A Patient with Eosinophilic Esophagitis and Herpes Simplex Esophagitis: A Case Report and Literature Review

Marella, Hemnishil K.; Kothadia, Jiten P.; Saleem, Nasir; Ali, Bilal; Abdel-Aziz, Yousef; Mupparaju, Vamsee; Oza, Twisha; Azouz, Abdallah; Howden, Colin W.

doi:10.1155/2021/5519635

Cited by 2 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only one serious AE (oesophageal herpes simplex virus [HSV]) was considered related to study drug, which resolved 21 days after onset following antiviral treatment. However, we note that studies have observed HSV infection in immunocompetent individuals with EoE, irrespective of topical corticosteroid use, raising doubts about this association 3,4 …”

mentioning

confidence: 78%

“…However, we note that studies have observed HSV infection in immunocompetent individuals with EoE, irrespective of topical corticosteroid use, raising doubts about this association. 3,4 Although 14.4% and 4.8% of participants receiving BOS 2.0 mg b.i.d. reported adrenal AEs and abnormal adrenocorticotropic stimulation tests, respectively, most were not considered related to study drug, were mild to moderate in severity and were not associated with signs or symptoms of glucocorticoid excess or adrenal dysfunction.…”

Section: Ae (Oesophageal Herpes Simplex Virus [Hsv]mentioning

confidence: 99%

See 1 more Smart Citation

Editorial: safety of topical steroids designed specifically for eosinophilic oesophagitis – new data bring new questions. Authors' reply

Hirano

Dellon

Gupta

et al. 2023

Aliment Pharmacol Ther

View full text Add to dashboard Cite

We thank Drs. Visaggi and Savarino for their interest in our study and insightful comments. 1,2 Our article provides a comprehensive overview of the safety outcomes following long-term treatment (up to 208 weeks) with budesonide oral suspension (BOS) in patients with eosinophilic oesophagitis (EoE). In our integrated safety analysis, BOS was well-tolerated, including in patients receiving the highest dose of BOS assessed to date (2.0 mg twice daily [b.i.d.]).We would like to emphasise that exposure-adjusted incidence rates per 100 participant-years were used to account for differences in treatment duration. Rates were similar for participants receiving BOS 2.0 mg b.i.d., BOS (any dose), and placebo for infections (133.5, 154.4, and 136.2), gastrointestinal effects (84.3, 80.9, and 92.1) and central nervous system (CNS)/mood effects (54.5, 63.7, and 52.1), and were only slightly higher for BOS than placebo for adrenal effects (44.8, 34.3, and 24.0). Importantly, most adverse events (AEs)were not serious, were not considered related to study drug and did not result in study or study drug discontinuation. Only one serious (equal); methodology (equal); project administration (equal); supervision (equal); writing -original draft (equal); writing -review and editing (equal). Mena Boules: Conceptualization (equal); data curation (equal); investigation (equal); methodology (equal); project administration (equal); supervision (equal); writing -original draft (equal); writing -review and editing (equal). Siddharth Bhatia: Conceptualization (equal); data curation (equal); investigation (equal); methodology (equal); project administration (equal); supervision (equal); writing -original draft (equal); writing -review and editing (equal). Nirav K. Desai: Conceptualization (equal); data curation (equal); investigation (equal); methodology (equal); project administration (equal); supervision (equal); writing -original draft (equal); writing -review and editing (equal).

show abstract

mentioning

confidence: 78%

Section: Ae (Oesophageal Herpes Simplex Virus [Hsv]mentioning

confidence: 99%

Editorial: safety of topical steroids designed specifically for eosinophilic oesophagitis – new data bring new questions. Authors' reply

Hirano

Dellon

Gupta

et al. 2023

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Герпесвирусный эзофагит подтверждается при позитивном иммуногистохимическом окрашивании с HSV I+II, положительной ПЦР на HSV и положительных серологических тестах с определением IgG и IgM к HSV. В наблюдениях на небольших группах пациентов описана связь герпесвирусного эзофагита с эозинофилией слизистой оболочки пищевода и ЭоЭ как у иммунокомпетентных детей, так и у иммунокомпрометированных взрослых [46][47][48][49]. Так, K.A.…”

Section: герпесвирусный эзофагитunclassified

Clinical and morphological diagnosis of eosinophilic esophagitis

Maslenkina,

Mikhaleva,

Motylev

et al. 2023

Clin. Exp. Morphology

View full text Add to dashboard Cite

Eosinophilic esophagitis (EoE) is an immune-mediated disease that presents with dysphagia and esophageal bolus obstruction and is characterized by predominant intraepithelial eosinophilic infiltration at histology. The aim of our literature review was to delineate clinical and morphological EoE features in terms of differential diagnosis with other esophageal diseases, i.e., gastroesophageal reflux disease (GERD), inflammatory bowel diseases (IBDs), autoimmune diseases, and rare esophageal disorders. Clinical features of dysphagia and esophageal bolus obstruction and endoscopic criteria (according to EREFS) are typical of EoE. Nevertheless, eosinophilia of the esophageal mucosa is not a specific marker of mucosal injury and is not sufficient for EoE diagnosis. Therefore, eosinophilic esophagitis histological scoring system (EoEHSS) was developed. It involves assessment of intraepithelial eosinophilic infiltration, basal zone hyperplasia, eosinophilic abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Complex clinical, endoscopic, and histological evaluation allows accurate diagnosis of EoE and other causal factors of esophageal eosinophilia. Keywords: eosinophilic esophagitis, esophageal eosinophilia, gastroesophageal reflux disease, celiac disease, inflammatory bowel diseases, achalasia, atopy

show abstract

A Patient with Eosinophilic Esophagitis and Herpes Simplex Esophagitis: A Case Report and Literature Review

Cited by 2 publications

References 15 publications

Editorial: safety of topical steroids designed specifically for eosinophilic oesophagitis – new data bring new questions. Authors' reply

Editorial: safety of topical steroids designed specifically for eosinophilic oesophagitis – new data bring new questions. Authors' reply

Clinical and morphological diagnosis of eosinophilic esophagitis

Contact Info

Product

Resources

About